Just a few weeks ago we announced our partnership with MedGenome. The news was covered by a number of outlets including:
Let me expIain the importance and impact of this announcement.
Since Varseq was released, we have received strong interest from testing labs that are leveraging our product to implement cancer diagnostic pipelines. Please feel free to take a look at my e-Book, Genetic Testing for Cancer, on this subject. Now, at Golden Helix we specialize in state of the art filtering and annotation capabilities. Our product ships with annotation sources such as COSMIC, which is a terrific first baseline.
However, our advanced users want more. MedGenome’s OncoMD is a comprehensive knowledge base providing those users with the following:
- A comprehensive catalogue of somatic and germ line mutations with over 1.8 million annotated cancer variants having genomic, CDS and protein level annotations
- Actionable mutations linked to approved drugs and open clinical trials to bridge the gap between clinical discovery and medical intervention
With MedGenome’s OncoMD, we are substantially improving the step from computing the variant list to creating a final report for our clients, enabling precision medicine. Please feel free to reach out to us at info@goldenhelix.com to learn more about how we have integrated OncoMD into VarSeq to maximize your user experience.